CureVac and Wacker sign manufacturing contract for COVID-19 vaccine candidate

MOSCOW (MRC) -- Wacker will support production of CureVac's COVID-19 mRNA-based vaccine candidate at its biotech site in Amsterdam, with production scheduled to start in the first half of 2021, as per BioPharm.On Nov. 23, 2020, biopharmaceutical company CureVac and contract development and manufacturing organization Wacker Chemie jointly announced that they have signed a contract for the

Full article at mrcplast.com